INS and type 2 diabetes mellitus: Based on the background of NVBP, the economic burden of insulin use for people with diabetes in China will be further reduced, it is necessary to evaluate the economics of IDegAsp from the perspective of China's health system, so as to provide valuable reference for decision makers in the choice of insulin treatment for T2DM in China.